We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

By LabMedica International staff writers
Posted on 05 Nov 2024

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. More...

However, training AI models requires large datasets, which are typically abundant for common diseases. The real challenge lies in accurately detecting rarer diseases, which many current AI models tend to overlook or misclassify. Researchers have now created a new AI tool designed to utilize imaging data to identify less common gastrointestinal tract diseases effectively.

Developed by scientists at Ludwig Maximilian University of Munich (Munich, Germany) and their collaborators, this innovative model only requires training data from frequently observed conditions to reliably detect rarer diseases. This advancement has the potential to enhance diagnostic accuracy and alleviate the workloads of pathologists in the future. As reported in the New England Journal of Medicine AI (NEJM AI), the new technique is founded on anomaly detection. The model learns to identify and highlight deviations from the precise characterization of normal tissues and findings from common diseases, without the need for specific training on these less frequent cases. The researchers utilized a dataset of 17 million histological images from 5,423 cases for training and evaluation.

In their research, the team gathered two extensive datasets of microscopic images from gastrointestinal biopsy tissue sections, along with their corresponding diagnoses. In these datasets, the ten most common findings—including normal observations and prevalent diseases such as chronic gastritis—constituted approximately 90% of cases, while the remaining 10% encompassed 56 different disease entities, including various cancers. Additionally, the AI model employs heatmaps to visually indicate the location of anomalies within the tissue section. By distinguishing normal findings and common diseases while detecting anomalies, the AI model is poised to offer crucial support to healthcare professionals. Although the identified diseases still require validation by pathologists, this AI tool can significantly reduce diagnostic time, as it enables automatic diagnosis of normal findings and a portion of diseases.

“We compared various technical approaches and our best model detected with a high degree of reliability a broad range of rarer pathologies of the stomach and colon, including rare primary or metastasizing cancers. To our knowledge, no other published AI tool is capable of doing this,” said Professor Frederick Klauschen, Director of the Institute of Pathology at LMU.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.